COMPOSITIONS COMPRISING ANTI-CEACAM1 AND ANTI-PD ANTIBODIES FOR CANCER THERAPY

• US 20170166637A1
• Filed: 11/25/2014
• Published: 06/15/2017
• Est. Priority Date: 11/25/2013
• Status: Active Grant

• Current Assignee: FameWave Ltd. (Purple Biotech Ltd.)
• Original Assignee: Ccam Biotherapeutics Ltd. (Merck & Co., Inc.)
• Inventors: BEN-MOSHE, Tehila, SAPIR, Yair, MANDEL, Ilana, MEILIN, Edna
• Granted Patent: US 10,081,679 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/464411 Immunoglobulin superfamily
• CPC Class Codes: A61K 39/464413 CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
• CPC Class Codes: A61K 39/464482 Carcinoembryonic antigen [CEA]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.

Claims

1-50. -50. (canceled)

51. A composition comprising:

a pharmaceutical composition comprising a monoclonal antibody to human CEACAM1 or an antigen-binding fragment thereof; and

a pharmaceutical composition comprising a monoclonal antibody to at least one of human PD-1, PD-L1 and PD-L2 or an antigen-binding fragment thereof wherein said pharmaceutical compositions are in separate containers.

60. A method for treating a patient having cancer, comprising the steps of separately administering to said patient:

(i) a pharmaceutical composition comprising a monoclonal antibody to human CEACAM1 or an antigen-binding fragment thereof; and

(ii) a pharmaceutical composition comprising a monoclonal antibody to at least one of human PD-1, PD-L1 and PD-L2 or an antigen-binding fragment thereof;

thereby treating said cancer.

68. A kit comprising:

(i) a pharmaceutical composition comprising a monoclonal antibody to human CEACAM1 or an antigen-binding fragment thereof; and

(ii) a pharmaceutical composition comprising a monoclonal antibody to at least one of human PD-1, PD-L1 and PD-L2 or an antigen-binding fragment thereof.